{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:47:37Z","timestamp":1791478057508,"version":"4.3.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shaanxi Province Natural Science Foundation Research Program","award":["2025JC-YBQN-1266"],"award-info":[{"award-number":["2025JC-YBQN-1266"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10787-026-02129-1","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T01:32:09Z","timestamp":1770600729000},"page":"1871-1888","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluating adverse events reported for non-steroidal anti-inflammatory drugs in osteoarthritis: a real-world pharmacovigilance study"],"prefix":"10.1007","volume":"34","author":[{"given":"Kesong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"issue":"5","key":"2129_CR1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.2042-7158.2012.01456.x","volume":"64","author":"A Adatia","year":"2012","unstructured":"Adatia A, Rainsford KD, Kean WF (2012) Osteoarthritis of the knee and hip. Part II: therapy with ibuprofen and a review of clinical trials. J Pharm Pharmacol 64(5):626\u2013636","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"2129_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.dld.2005.09.003","volume":"38","author":"MM Aloysius","year":"2006","unstructured":"Aloysius MM, Kaye PV, Lobo DN (2006) Non-steroidal anti-inflammatory drug (NSAID)-induced colonic strictures and perforation: a case report. Dig Liver Dis 38(4):276\u2013278","journal-title":"Dig Liver Dis"},{"key":"2129_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/818259","volume":"2013","author":"N Artom","year":"2013","unstructured":"Artom N, Oddo S, Pende A, Ottonello L, Giusti M, Dallegri F (2013) Syndrome of inappropriate antidiuretic hormone secretion and ibuprofen, a rare association to be considered: role of tolvaptan. Case Rep Endocrinol 2013:1\u20134","journal-title":"Case Rep Endocrinol"},{"issue":"2","key":"2129_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40744-020-00196-6","volume":"7","author":"F Bariguian Revel","year":"2020","unstructured":"Bariguian Revel F, Fayet M, Hagen M (2020) Topical diclofenac, an efficacious treatment for osteoarthritis: a narrative review. Rheumatol Ther 7(2):217\u2013236","journal-title":"Rheumatol Ther"},{"issue":"4","key":"2129_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3810\/pgm.2014.07.2786","volume":"126","author":"AE Bello","year":"2015","unstructured":"Bello AE, Kent JD, Grahn AY, Rice P, Holt RJ (2015) Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen\/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. Postgrad Med 126(4):82\u201391","journal-title":"Postgrad Med"},{"issue":"9894","key":"2129_CR6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA et al (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. The Lancet 382(9894):769\u2013779","journal-title":"The Lancet"},{"key":"2129_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020355","author":"MD Brandt","year":"2025","unstructured":"Brandt MD, Malone JB, Kean TJ (2025) Advances and challenges in the pursuit of disease-modifying osteoarthritis drugs: a review of 2010\u20132024 clinical trials. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines13020355","journal-title":"Biomedicines"},{"issue":"9549","key":"2129_CR8","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","volume":"368","author":"CP Cannon","year":"2006","unstructured":"Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA et al (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. The Lancet 368(9549):1771\u20131781","journal-title":"The Lancet"},{"issue":"2","key":"2129_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/PL00011190","volume":"20","author":"DM Chang","year":"2001","unstructured":"Chang DM, Young TH, Hsu CT, Kuo SY, Hsieh TC (2001) Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis. Clin Rheumatol 20(2):104\u2013113","journal-title":"Clin Rheumatol"},{"issue":"7","key":"2129_CR10","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/pds.1409","volume":"16","author":"LC Chen","year":"2007","unstructured":"Chen LC, Ashcroft DM (2007) Risk of myocardial infarction associated with selective COX\u20102 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf 16(7):762\u2013772","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2129_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.12659\/AJCR.926561","volume":"21","author":"C-Y Chiu","year":"2020","unstructured":"Chiu C-Y, Sarwal A, Azhar Munir R, Widjaja M, Khalid A, Khanna R (2020) Syndrome of Inappropriate Antidiuretic Hormone (SIADH) induced by long-term use of citalopram and short-term use of naproxen. Am J Case Rep 21:2","journal-title":"Am J Case Rep"},{"issue":"S1","key":"2129_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40266-019-00664-x","volume":"36","author":"E Curtis","year":"2019","unstructured":"Curtis E, Fuggle N, Shaw S, Spooner L, Ntani G, Parsons C et al (2019) Safety of cyclooxygenase-2 inhibitors in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging 36(S1):25\u201344","journal-title":"Drugs Aging"},{"issue":"6","key":"2129_CR13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1136\/ard.2006.066001","volume":"66","author":"ME Farkouh","year":"2007","unstructured":"Farkouh ME, Greenberg JD, Jeger RV, Ramanathan K, Verheugt FWA, Chesebro JH et al (2007) Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 66(6):764\u2013770","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2129_CR14","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V et al (2024) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement. Drug Saf 47(6):575\u2013584","journal-title":"Drug Saf"},{"issue":"12","key":"2129_CR15","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s40264-025-01624-8","volume":"48","author":"M Fusaroli","year":"2025","unstructured":"Fusaroli M, Sartori D, van Puijenbroek EP, Nor\u00e9n GN (2025) Charting and sidestepping the pitfalls of disproportionality analysis. Drug Saf 48(12):1663\u20131664","journal-title":"Drug Saf"},{"issue":"1","key":"2129_CR16","volume":"2005","author":"SE Garner","year":"2005","unstructured":"Garner SE, Fidan DD, Frankish R, Maxwell L (2005) Rofecoxib for osteoarthritis. Cochrane Database Syst Rev 2005(1):CD005115","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2129_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1365-2036.2010.04378.x","volume":"32","author":"JL Goldstein","year":"2010","unstructured":"Goldstein JL, Hochberg MC, Fort JG, Zhang Y, Hwang C, Sostek M (2010) Clinical trial: the incidence of NSAID\u2010associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric\u2010coated naproxen alone. Aliment Pharmacol Ther 32(3):401\u2013413","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2129_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1542-3565(04)00603-2","volume":"3","author":"DY Graham","year":"2005","unstructured":"Graham DY, Opekun AR, Willingham FF, Qureshi WA (2005) Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 3(1):55\u201359","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"2129_CR19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40264-024-01433-5","volume":"47","author":"CA Gravel","year":"2024","unstructured":"Gravel CA, Bai W, Douros A (2024) Comparators in pharmacovigilance: a quasi-quantification bias analysis. Drug Saf 47(8):809\u2013819","journal-title":"Drug Saf"},{"issue":"1","key":"2129_CR20","doi-asserted-by":"publisher","first-page":"21341","DOI":"10.1038\/s41598-025-05709-3","volume":"15","author":"S-Y Hong","year":"2025","unstructured":"Hong S-Y, Zhou C-B, Chen X-D, Zhu G-P, Gao C-H, Wang P-H (2025) Pharmacovigilance study of drug-induced eye movement disorder based on FDA adverse event reports from 2004 to 2024. Sci Rep 15(1):21341","journal-title":"Sci Rep"},{"issue":"S1","key":"2129_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40266-019-00661-0","volume":"36","author":"G Honvo","year":"2019","unstructured":"Honvo G, Leclercq V, Geerinck A, Thomas T, Veronese N, Charles A et al (2019) Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging 36(S1):45\u201364","journal-title":"Drugs Aging"},{"issue":"3 Pt 1","key":"2129_CR22","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1164\/ajrccm.157.3.9701093","volume":"157","author":"R Hubbard","year":"1998","unstructured":"Hubbard R, Venn A, Smith C, Cooper M, Johnston I, Britton J (1998) Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis a case-control study. Am J Respir Crit Care Med 157(3 Pt 1):743\u2013747","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"2129_CR23","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jpain.2011.03.003","volume":"12","author":"K Kroenke","year":"2011","unstructured":"Kroenke K, Wu J, Bair MJ, Krebs EE, Damush TM, Tu W (2011) Reciprocal relationship between pain and depression: a 12-month longitudinal analysis in primary care. J Pain 12(9):964\u2013973","journal-title":"J Pain"},{"issue":"9560","key":"2129_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0140-6736(07)60234-7","volume":"369","author":"L Laine","year":"2007","unstructured":"Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP (2007) Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 369(9560):465\u2013473","journal-title":"Lancet"},{"issue":"3","key":"2129_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/ajg.2011.443","volume":"107","author":"L Laine","year":"2012","unstructured":"Laine L, Kivitz AJ, Bello AE, Grahn AY, Schiff MH, Taha AS (2012) Double-blind randomized trials of single-tablet ibuprofen\/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 107(3):379\u2013386","journal-title":"Am J Gastroenterol"},{"key":"2129_CR26","doi-asserted-by":"publisher","first-page":"1498191","DOI":"10.3389\/fphar.2025.1498191","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Wang SW, Zhang Z-J, Luo ZY, Tang JF, Tao T (2025) Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database. Front Pharmacol\u00a016:1498191","journal-title":"Front Pharmacol"},{"key":"2129_CR27","doi-asserted-by":"publisher","first-page":"119484","DOI":"10.1016\/j.jad.2025.119484","volume":"387","author":"J Lin","year":"2025","unstructured":"Lin J, Wei S, Peng Y, Liang C, Jiao W, Ji Y et al (2025) Gastrointestinal adverse events associated with SNRIs: a FAERS-based pharmacovigilance study. J Affect Disord\u00a0387:119484","journal-title":"J Affect Disord"},{"key":"2129_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/bmb\/lds038","volume":"105","author":"A Litwic","year":"2013","unstructured":"Litwic A, Edwards MH, Dennison EM, Cooper C (2013) Epidemiology and burden of osteoarthritis. Br Med Bull 105:185\u2013199","journal-title":"Br Med Bull"},{"key":"2129_CR29","doi-asserted-by":"publisher","first-page":"119517","DOI":"10.1016\/j.jad.2025.119517","volume":"388","author":"D Liu","year":"2025","unstructured":"Liu D, Li N, Liu L, Qiu L, Zhou Z, Wu J (2025a) Uncovering safety signals of duloxetine: real-world evidence from the FAERS database. J Affect Disord\u00a0388:119517","journal-title":"J Affect Disord"},{"issue":"8","key":"2129_CR30","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1007\/s00787-025-02694-w","volume":"34","author":"J Liu","year":"2025","unstructured":"Liu J, Xue L, Zeng F, Liu Y, Zhu Y, Zhou J et al (2025b) Exploring the potential association between stimulant or atomoxetine use and suicidal or self-injurious behaviors in children with attention deficit hyperactivity disorder: real-world insights from the FAERS database. Eur Child Adolesc Psychiatry 34(8):2585\u20132597","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"3","key":"2129_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1136\/ard.2004.023572","volume":"64","author":"LS Lohmander","year":"2005","unstructured":"Lohmander LS, McKeith D, Svensson O, Malmen\u00e4s M, Bolin L, Kalla A et al (2005) A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 64(3):449\u2013456","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2129_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.molmed.2021.12.007","volume":"28","author":"J Loughlin","year":"2022","unstructured":"Loughlin J (2022) Translating osteoarthritis genetics research: challenging times ahead. Trends Mol Med 28(3):176\u2013182","journal-title":"Trends Mol Med"},{"key":"2129_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.72","volume":"2","author":"J Martel-Pelletier","year":"2016","unstructured":"Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB et al (2016) Osteoarthritis. Nat Rev Dis Primers 2:16072","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"2129_CR34","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2165\/00003495-200161060-00019","volume":"61","author":"AJ Matheson","year":"2001","unstructured":"Matheson AJ, Figgitt DP (2001) Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. Drugs 61(6):833\u2013865","journal-title":"Drugs"},{"issue":"7","key":"2129_CR35","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/sj.mp.4001805","volume":"11","author":"N M\u00fcller","year":"2006","unstructured":"M\u00fcller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-M\u00fcller B et al (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11(7):680\u2013684","journal-title":"Mol Psychiatry"},{"issue":"2","key":"2129_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000107420","volume":"14","author":"AM Myint","year":"2007","unstructured":"Myint AM, Steinbusch HWM, Goeghegan L, Luchtman D, Kim YK, Leonard BE (2007) Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. NeuroImmunoModulation 14(2):65\u201371","journal-title":"NeuroImmunoModulation"},{"issue":"2","key":"2129_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000334685","volume":"85","author":"Y Nagano","year":"2012","unstructured":"Nagano Y, Matsui H, Tamura M, Shimokawa O, Nakamura Y, Kaneko T et al (2012) NSAIDs and acidic environment induce gastric mucosal cellular mitochondrial dysfunction. Digestion 85(2):131\u2013135","journal-title":"Digestion"},{"issue":"4","key":"2129_CR38","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/mr\/road100","volume":"34","author":"Y Nishida","year":"2024","unstructured":"Nishida Y, Yagami A, Takada S, Muramatsu D, Nobuoka Y, Okayama Y (2024) Clinical investigation for the mechanisms of anaphylactic symptoms in osteoarthritis patients after diclofenac etalhyaluronate administration. Mod Rheumatol 34(4):820\u2013830","journal-title":"Mod Rheumatol"},{"issue":"6","key":"2129_CR39","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","volume":"22","author":"Y Noguchi","year":"2021","unstructured":"Noguchi Y, Tachi T, Teramachi H (2021) Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform\u00a022(6):bbab347","journal-title":"Brief Bioinform"},{"issue":"12","key":"2129_CR40","doi-asserted-by":"publisher","first-page":"e0261239","DOI":"10.1371\/journal.pone.0261239","volume":"16","author":"M Nurmohamed","year":"2021","unstructured":"Nurmohamed M, Cheng B-R, Chen J-Q, Zhang X-W, Gao Q-Y, Li W-H et al (2021) Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: a systematic review and meta-analysis. PLoS ONE 16(12):e0261239","journal-title":"PLoS ONE"},{"issue":"7","key":"2129_CR41","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S0149-2918(01)80092-8","volume":"23","author":"JM Pellissier","year":"2001","unstructured":"Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE (2001) Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis. Clin Ther 23(7):1061\u20131079","journal-title":"Clin Ther"},{"issue":"3","key":"2129_CR42","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cpt.3701","volume":"118","author":"E Potter","year":"2025","unstructured":"Potter E, Reyes M, Naples J, Dal Pan G (2025) FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS. Clin Pharmacol Ther 118(3):567\u2013582","journal-title":"Clin Pharmacol Ther"},{"key":"2129_CR43","doi-asserted-by":"crossref","unstructured":"Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P (2017) Celecoxib for osteoarthritis. Cochrane Database Syst Rev 2017(7)","DOI":"10.1002\/14651858.CD009865.pub2"},{"issue":"12","key":"2129_CR44","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.joca.2007.05.022","volume":"15","author":"A Puopolo","year":"2007","unstructured":"Puopolo A, Boice JA, Fidelholtz JL, Littlejohn TW, Miranda P, Berrocal A et al (2007) A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthr Cartil 15(12):1348\u20131356","journal-title":"Osteoarthr Cartil"},{"issue":"7","key":"2129_CR45","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.amjmed.2005.10.056","volume":"119","author":"SR Salpeter","year":"2006","unstructured":"Salpeter SR, Gregor P, Ormiston TM, Whitlock R, Raina P, Thabane L et al (2006) Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med 119(7):552\u2013559","journal-title":"Am J Med"},{"issue":"10","key":"2129_CR46","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR (2013) Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf 36(10):995\u20131006","journal-title":"Drug Saf"},{"issue":"3","key":"2129_CR47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2165\/00002018-200427030-00003","volume":"27","author":"H Schmidt","year":"2004","unstructured":"Schmidt H, Woodcock BG, Geisslinger G (2004) Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis. Drug Saf 27(3):185\u2013196","journal-title":"Drug Saf"},{"issue":"3","key":"2129_CR48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.amjmed.2005.09.054","volume":"119","author":"G Singh","year":"2006","unstructured":"Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE et al (2006) Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 119(3):255\u2013266","journal-title":"Am J Med"},{"issue":"2","key":"2129_CR49","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/ageing\/afw001","volume":"45","author":"B Stubbs","year":"2016","unstructured":"Stubbs B, Aluko Y, Myint PK, Smith TO (2016) Prevalence of depressive symptoms and anxiety in osteoarthritis: a systematic review and meta-analysis. Age Ageing 45(2):228\u2013235","journal-title":"Age Ageing"},{"issue":"5S","key":"2129_CR50","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.pmrj.2012.01.007","volume":"4","author":"P Suri","year":"2012","unstructured":"Suri P, Morgenroth DC, Hunter DJ (2012) Epidemiology of Osteoarthritis and Associated Comorbidities. Pm & R 4(5S):S10","journal-title":"Pm & R"},{"issue":"6","key":"2129_CR51","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2165\/00019053-200321060-00007","volume":"21","author":"M Tavakoli","year":"2003","unstructured":"Tavakoli M (2003) Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam. Pharmacoeconomics 21(6):443\u2013454","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2129_CR52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/15360288.2017.1301616","volume":"31","author":"V Tieppo Francio","year":"2017","unstructured":"Tieppo Francio V, Davani S, Towery C, Brown TL (2017) Oral versus topical diclofenac sodium in the treatment of osteoarthritis. J Pain Palliat Care Pharmacother 31(2):113\u2013120","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"1","key":"2129_CR53","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13075-015-0554-0","volume":"17","author":"A van Walsem","year":"2015","unstructured":"Van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA (2015) Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther\u00a017(1):66","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2129_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12325-019-01144-9","volume":"37","author":"G Varrassi","year":"2019","unstructured":"Varrassi G, Pergolizzi JV, Dowling P, Paladini A (2019) Ibuprofen safety at the golden anniversary: Are all NSAIDs the same? A narrative review. Adv Ther 37(1):61\u201382","journal-title":"Adv Ther"},{"issue":"4","key":"2129_CR55","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1152\/physrev.00004.2008","volume":"88","author":"JL Wallace","year":"2008","unstructured":"Wallace JL (2008) Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn\u2019t the stomach digest itself? Physiol Rev 88(4):1547\u20131565","journal-title":"Physiol Rev"},{"key":"2129_CR56","doi-asserted-by":"publisher","first-page":"1563238","DOI":"10.3389\/fphar.2025.1563238","volume":"16","author":"T Wang","year":"2025","unstructured":"Wang T, He G, Xiong W, Huang J (2025) Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database. Front Pharmacol 16:1563238","journal-title":"Front Pharmacol"},{"issue":"4","key":"2129_CR57","doi-asserted-by":"publisher","first-page":"470","DOI":"10.4065\/80.4.470","volume":"80","author":"CW Wiesenhutter","year":"2005","unstructured":"Wiesenhutter CW, Boice JA, Ko A, Sheldon EA, Murphy FT, Wittmer BA et al (2005) Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 80(4):470\u2013479","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2129_CR58","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40264-016-0405-1","volume":"39","author":"AFZ Wisniewski","year":"2016","unstructured":"Wisniewski AFZ, Bate A, Bousquet C, Brueckner A, Candore G, Juhlin K et al (2016) Good signal detection practices: evidence from IMI PROTECT. Drug Saf 39(6):469\u2013490","journal-title":"Drug Saf"},{"issue":"6","key":"2129_CR59","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00223-014-9917-9","volume":"95","author":"B Xia","year":"2014","unstructured":"Xia B, Di C, Zhang J, Hu S, Jin H, Tong P (2014) Osteoarthritis pathogenesis: a review of molecular mechanisms. Calcif Tissue Int 95(6):495\u2013505","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2129_CR60","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s13018-023-03786-6","volume":"18","author":"F Zeng","year":"2023","unstructured":"Zeng F, Wang K, Duan H, Xu X-t, Kuang G-y, Lu M (2023) Diacerein versus non-steroidal anti-inflammatory drugs in the treatment of knee osteoarthritis: a meta-analysis. J Orthop Surg Res\u00a018(1):308","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"2129_CR61","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1186\/s12885-025-14227-4","volume":"25","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Zheng J, Liang Y, Wu Q, Ding C, Ma L et al (2025a) Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. BMC Cancer\u00a025(1):846","journal-title":"BMC Cancer"},{"key":"2129_CR62","doi-asserted-by":"publisher","first-page":"177429","DOI":"10.1016\/j.ejphar.2025.177429","volume":"999","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Qian M, Zheng A, Chen Y, Li B, Tang J et al (2025b) The risk of propofol infusion syndrome on epilepsy patients:insights from FAERS data and published case reports. Eur J Pharmacol\u00a0999:177429","journal-title":"Eur J Pharmacol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02129-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02129-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02129-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:03:57Z","timestamp":1773777837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-026-02129-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2129"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02129-1","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The research utilized exclusively publicly available data from open-access databases. As such, this study did not involve direct human subject participation or collection of private health information, and therefore did not require institutional review board approval or informed consent procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have thoroughly reviewed and approved the final version of the manuscript for publication. Each author has provided explicit consent for the manuscript\u2019s submission and agrees to its publication in its current form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}